

Guideline Page and Request	Panel Discussion/References	Institution Vote			
		YES	NO	ABSTAIN	ABSENT
<p>Internal Request: In response to the FDA approval of cabozantinib plus nivolumab as a first-line therapy for patients with favorable-risk and poor/intermediate-risk clear cell renal cell carcinoma (RCC), the Panel requested the addition of cabozantinib plus nivolumab for these indications.</p> <p>External Request: Submission from Bristol Myers Squibb request for the Panel to consider adding nivolumab in combination with cabozantinib to the NCCN Kidney Cancer Guidelines as a preferred, category 1 first-line treatment option for advanced renal cell carcinoma patients. (Page KID-C 1 of 2)</p> <p>Submission from Exelixis requests for the Panel to consider a category 1, preferred regimen recommendation for cabozantinib in combination with nivolumab as a first-line treatment in patients with advanced renal cell carcinoma (aRCC), regardless of International Metastatic RCC Database Consortium (IMDC) risk group. Cabozantinib, in combination with nivolumab, is now FDA-approved for first-line treatment of patients with aRCC.</p>	<p>Based on the review of the data in the noted reference, and the recent FDA approval, the Panel consensus was to include:</p> <ul style="list-style-type: none"> • Cabozantinib plus nivolumab as a first-line therapy option for favorable-risk clear cell RCC. This is a category 2A, Preferred recommendation. • Cabozantinib plus nivolumab as a first-line therapy option for poor-intermediate risk clear cell RCC. This is a category 2A, Preferred recommendation. <p>The Panel consensus was to wait for publication of the data to review the category 1 designation.</p> <p>Reference: Choueiri T, et al. Nivolumab + cabozantinib vs sunitinib in first-line treatment for advanced renal cell carcinoma: First results from the randomized phase III CheckMate 9ER trial [abstract]. Annals of Oncology (2020) 31 (suppl_4): Abstract 6960_PR.</p>	15	6	1	9